PHILADELPHIA – Vivodyne, a pioneering biotech company that grows and tests on lab-grown human tissues to accelerate therapeutics discovery and development, today announced the appointment of Julie O’Shaughnessy as Chief Operating Officer. In her new role, Julie will oversee business operations, strategic planning, finance, people operations, and multisite expansion, driving the company’s operational excellence and strategic growth initiatives. “Julie has been instrumental in Vivodyne’s growth … Continue reading Vivodyne Appoints Julie O’Shaughnessy as Chief Operating Officer

Adds Highly Complementary Business in Gene Expression Profiling and Spatial Transcriptomics for Discovery and Translational Research BILLERICA, Mass.–(BUSINESS WIRE)–Bruker Corporation (Nasdaq: BRKR) today announced that it has closed its asset acquisition of the business of NanoString Technologies, Inc., headquartered in Seattle, Washington, a leading provider of life-science research solutions for spatial transcriptomics and gene expression analysis. “We have a proven track record in successfully integrating and nurturing … Continue reading Bruker Completes Asset Acquisition of NanoString Business

SANTA CLARA, Calif. – Agilent Technologies Inc. (NYSE:A) today announced that Padraig McDonnell has assumed the role of Agilent CEO, effective immediately. His appointment is part of the company’s CEO transition plan announced Feb. 21. McDonnell is the fourth CEO in Agilent’s history and succeeds Mike McMullen, who will serve as an adviser until he retires Oct. 31. “It’s an incredible honor to serve as CEO … Continue reading Padraig McDonnell Assumes Agilent CEO Role

Modalis Joins Ginkgo’s Technology Network TOKYO & WALTHAM, Mass.–(BUSINESS WIRE)–Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) announced that it has entered into an agreement with Ginkgo Bioworks (Ginkgo) to join the Ginkgo Technology Network. This strategic alliance will enable Ginkgo’s global customers in the cell and gene therapy fields to access Modalis’ proprietary epigenome modulation technology, CRISPR-GNDM® (Guide Nucleotide-Directed Modulation). Modalis’ CRISPR-GNDM® Technology is capable of activating … Continue reading Modalis Announces Partnership with Ginkgo Bioworks

MCLEAN, Va.–(BUSINESS WIRE)–Zephyr AI, Inc. (“Zephyr AI”), a healthcare technology company committed to developing fast and explainable artificial intelligence (AI) solutions to democratize precision medicine, today announced the appointment of Rachael Brake, PhD, as its new Chief Scientific Officer. “Having spent decades working in big pharma and biotech spanning roles in research, development and commercial, Rachael comes to Zephyr with a unique breadth of experience”Post this … Continue reading Rachael Brake, PhD, Joins Zephyr AI as Chief Scientific Officer